Skyrizi喜開悅

Skyrizi

risankizumab

Manufacturer:

AbbVie

Distributor:

The Glory Medicina
/
DKSH
Concise Prescribing Info
Contents
Risankizumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Dosage/Direction for Use
150 mg SC at wk 0, wk 4, & every 12 wk thereafter.
Contraindications
Hypersensitivity. Clinically important active infections (eg, active TB).
Special Precautions
Patients w/ chronic infection, history of recurrent infection, or known risk factors for infection. Do not initiate treatment w/ risankizumab in patients w/ clinically important active infection until it resolves or is adequately treated. Evaluate for TB prior to initiating treatment. Monitor for signs & symptoms of active TB. Patients should not receive live vaccines during treatment & for at least 21 wk after treatment. Wait at least 4 wk prior to starting treatment in patient who has received live vaccination. If serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately & appropriate therapy initiated. Contains sorbitol. Women of childbearing potential should use an effective method of contraception during treatment & for at least 21 wk after treatment. Pregnancy & lactation.
Adverse Reactions
Upper resp infections (eg, sinusitis, rhinitis, nasopharyngitis, tonsillitis). Tinea infections (eg, tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, onychomycosis); headache (eg, tension headache, sinus headache); pruritus; fatigue (eg, asthenia), inj site reactions (eg, inj site bruising, erythema, haematoma, haemorrhage, irritation, pain, pruritus, reaction, swelling).
ATC Classification
L04AC18 - risankizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Skyrizi soln for inj 75 mg/0.83 mL
Packing/Price
2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in